Immunovia AB (publ) - Special Call Transcript
()-
Good afternoon, everyone. My name is Patrik Dahlen. I am the CEO of Immunovia, and I will be the moderator of this webinar. A very warm welcome to all of you to this Immunovia webinar.
With me on this webinar call are Dr. Thomas King, who is our Medical Director; Dr. Linda Mellby, who is our Vice President of R&D; and Dr. Laura Chirica, who is our Chief Commercial Officer.
This is the third webinar in a series of webinars that we have run since the beginning of this summer. Today's webinar is called IMMray PanCan-d Verification Study and Clinical Use. The agenda for the webinar is positioning of IMMray PanCan-d in clinical practice, this will be presented by Dr. King; the verification study versus clinical practice, this will be presented by Linda Mellby; and the voice of the pancreatic cancer experts about IMMray PanCan-d clinical utility, and this will be presented by Laura, who is our Chief Commercial Officer.
Please remember that at the end of the webinar, you will have a chance to ask questions.
Access to All Earning Calls and Stock Analysis | |
30-Year Financial on one screen | |
All-in-one Stock Screener with unlimited filters | |
Customizable Stock Dashboard | |
Real Time Insider Trading Transactions | |
8,000+ Institutional investors’ 13F holdings | |
Powerful Excel Add-in and Google sheets Add-on | |
All data downloadable | |
Quick customer support | |
And much more... |